Clinical trials: Neonatal Respiratory Failure

Apnea of Prematurity, Respiratory Insufficiency

Doxapram Therapy in Preterm Infants (DOXA Trial)

• Recruiting
• Age: 23 to 29 weeks
• Phase 3

Preterm infants often suffer from apnea of prematurity (AOP; a cessation of breathing) due to immaturity of the respiratory system.

Trial name

NCT04430790

Testing

Doxapram

Where

24 sites in Belgium, Canada and 1 more

Volunteers

396 people

Sponsor

Erasmus Medical Center